Abstract
Unlike lower vertebrates, mammals are unable to replace damaged mechanosensory hair cells (HCs) in the cochlea. Recently, ablation of the retinoblastoma protein (Rb) in undifferentiated mouse HC precursors was shown to cause cochlear HC proliferation and the generation of new HCs, raising the hope that inactivation of Rb in postmitotic HCs could trigger cell division and regenerate functional HCs postnatally. Here, we acutely inactivated Rb in nearly all cochlear HCs of newborn mice, using a newly developed HC-specific inducible Cre mouse line. Beginning 48 h after Rb deletion, ≈40% of HCs were in the S and M phases of the cell cycle, demonstrating an overriding role for Rb in maintaining the quiescent state of postnatal HCs. Unlike Rb-null HC precursors, such HCs failed to undergo cell division and died rapidly. HC clusters were restricted to the less differentiated cochlear regions, consistent with differentiation-dependent roles of Rb. Moreover, outer HCs expressed the maturation marker prestin, suggesting an embryonic time window for Rb-dependent HC specification. We conclude that Rb plays essential and age-dependent roles during HC proliferation and differentiation, and, in contrast to previous hypotheses, cell death after forced cell-cycle reentry presents a major challenge for mammalian HC regeneration from residual postnatal HCs.
Keywords: prestin, regeneration
Cochlear hair cells (HCs) in the mammalian inner ear are mechanosensory receptors that transduce sound into electrical signals. HCs and their surrounding supporting cells (SCs) derive from common precursors during the embryonic development of the inner ear. In mice, these progenitors exit the cell cycle approximately on embryonic days (E)13–14 and become quiescent (1–3). Permanent cell-cycle exit is followed by differentiation into SCs and HCs later in embryonic development and functional subdifferentiation into inner and outer HCs (IHCs and OHCs) postnatally (reviewed in ref. 4).
Genetic and environmental factors, such as noise and ototoxic drugs, can damage HCs, leading to their death and to permanent hearing loss. Mammalian HCs are not regenerated, whereas nonmammalian vertebrates are able to replenish lost sensory HCs by proliferation and differentiation of nearby SCs within the sensory epithelium (5–7). The critical difference in the regenerative ability of mammalian cochleae and nonmammalian hearing organs appears to be their proliferative responsiveness after trauma.
A key inhibitor of proliferation is the retinoblastoma protein (Rb), a member of the family of pocket domain proteins. These proteins bind to E2F transcription factors and can repress genes required during the S phase, thereby maintaining cells in a quiescent state (reviewed in ref. 8). Rb is expressed in embryonic and postnatal HCs; its absence in HC precursors of mice led to the production of supernumerary HCs that appeared functional, demonstrating that mammalian HC precursors can indeed be manipulated to proliferate (9, 10). However, HC injury typically occurs after birth; our aim was therefore to determine whether the inactivation of Rb could trigger cell-cycle reentry in postnatal HCs. The consequences of Rb loss in vivo have been studied in many tissues, using mouse models (11); in this study, we inactivated Rb in postnatal HCs, using a newly developed tamoxifen-inducible Cre mouse line. We observed that HCs rapidly reentered the cell cycle after the loss of Rb but died without generating supernumerary HCs. Thus, forced cell-cycle reentry by Rb inactivation had an entirely different outcome in postnatal HCs than in embryonic precursor cells for HCs and SCs, having limited use for hair cell regeneration.
Results
Inducible Inactivation of Rb Function in Postnatal Cochlear HCs.
We used the Cre-loxP system (12) to ablate Rb function in postmitotic HCs. A gene-targeted mouse (Rblox/lox) with exon 19 of the Rb gene flanked by two loxP sites (13) was crossed with the Atoh1-CreERTM mice that exhibited inducible Cre activity specifically in nearly all cochlear HCs when injected with tamoxifen once a day on postnatal days (P) 0 and P1 [unless stated otherwise; Fig. 1 and refs. 14 and 15]. The mice used were tamoxifen-injected Atoh1-CreERTM:Rblox/lox (designated Rb−/−), Atoh1-CreERTM:Rb+/lox (Rb+/−), and Atoh1-CreERTM-negative:Rblox/lox mice (Rblox/lox) mice. Among the offspring, three possible Rb alleles—wild-type, floxed (unrecombined), and inactivated (recombined)—were confirmed subsequently by PCR, using genomic DNA extracted from the cochlea (Fig. 1A). To determine the onset of Cre activity, we administered a single tamoxifen injection on P0 and observed recombination after 30 h but not after 6, 12, 18, or 24 h (Fig. 1B). Therefore, the time required for the absorption of tamoxifen, translocation of CreERTM recombinase into the nucleus, and efficient recombination in HCs is between 24 and 30 h after injections on P0. We did not observe phenotypes in Rb+/− mice or in most other tissues, and mice of all genotypes survived well into adulthood (data not shown; see ref. 14).
Rapid HC Loss upon Acute Inactivation of Rb.
To determine whether postmitotic HCs proliferate in the absence of Rb, we dissected cochleae from Rb−/− and Rb+/− mice. On P3, confocal scans of cochlear whole mounts stained with HC markers revealed a wild-type-like morphology of the organ of Corti in all genotypes (Fig. 2 A and B). These findings underlined that, until P3, Rb−/− HCs had undergone normal development, including regular cell-cycle exit.
When HC numbers were analyzed in cochlear whole mounts after P3, we found that IHC and OHC numbers in Rb−/− mice decreased rapidly between P4 and P15 relative to those in Rb+/− mice, without signs of additional HCs at any stage (Fig. 2). By P15, nearly all HCs were lost in Rb−/− mice, whereas Rb+/− littermates had a normal organ of Corti without HC loss at all ages, indicating that one copy of Rb is sufficient to maintain quiescence and survival of postmitotic HCs (Fig. 2D). Furthermore, it can be deduced that after the recombination of the Rb gene locus, turnover of endogenous Rb in HCs and subsequent processes leading to HC loss span a period of 2–3 days. Consistently, when tested after 6 weeks, using click auditory brainstem responses, all Rb−/− mice displayed profound hearing loss [thresholds >85 sound pressure level (dB SPL), n = 7], whereas Rb+/− and Rblox/lox mice had normal hearing (thresholds ≈25 dB SPL, n = 11 and 2, respectively) (data not shown; procedures are described in ref. 16).
Rapid Cell-Cycle Reentry and Cell Death of Postmitotic HCs.
To investigate whether postmitotic HCs would reenter the cell cycle upon acute loss of Rb function, we gave mice i.p. injections of 5-bromo-2′-deoxyuridine and 5-fluoro-2′-deoxyuridine (BrdU) on P4 every 2 h for five consecutive doses and analyzed them 12 h after the first injection. Cells entering the S phase within 12 h on P4 and thus incorporating BrdU into replicated DNA should have been detectable by using anti-BrdU immunostaining. In Rb+/− littermates, no BrdU-positive HC nuclei were detected (Fig. 3A), whereas ≈40% of the HC nuclei in Rb−/− mice were BrdU-positive (Fig. 3B). Such nuclei appeared in basal and apical cochlear turns at similar rates (data not shown). Their high percentage within a 12 h time window, 4 days after the first tamoxifen injection and 2–3 days after the recombination of the Rb gene locus, indicated a synchronized S phase entry of HCs. BrdU-positive cells within the organ of Corti were costained with the HC marker myosin7a, indicating that no cell-cycle reentry of SCs had occurred.
Changes in chromatin conformation at the onset of the M phase involve the phosphorylation of histone H3. Antibodies against phosphorylated Ser-10 of histone H3 stained the nuclei in HCs of Rb−/− mice (Fig. 3C) but not in those of Rb+/− littermates on P5 (data not shown). Consistently, changes in chromatin conformation in Rb−/− HC nuclei were revealed by 4′, 6-diamidino-2-phenylindole (DAPI) staining (Fig. 3D). In addition, HCs were rounding up, indicative of mitosis (Fig. 3D). High-resolution microscopy further identified mitotic HC nuclei based on morphologic features, such as the appearance of individual chromosomes in prophase (Fig. 3E). By counting such mitotic nuclei in two littermates on P4, we determined that ≈28% of HCs were in the M phase (Fig. 3 E and F). Thus, it is clear that ≈40% of HCs had reentered the cell cycle at P4. Mitotic cells were observed in basal and apical locations (Fig. 3 E and F). M phase entry of Rb−/− HCs generally correlated with the migration of the cell nucleus from a basal to a more apical subcellular location; consequently, these HCs did not align in the plane with “normal” HC nuclei (Fig. 3 D–F). Similar phenomena have been observed in normal dividing cells in the developing retina (17).
To characterize the HC death, we performed terminal transferase dUTP nick-end labeling (TUNEL), which detects breakage in nuclear DNA, characteristic for cells dying from apoptosis. On P4, weakly to brightly labeled OHC and IHC nuclei were observed, indicating early or late stages of apoptotic HC death (Fig. 3 G and H; data not shown). Scanning whole mounts of Rb−/− cochleae within the HC nuclear layer, we observed abnormal kidney-shaped and quasi-binucleated HC nuclei (Fig. 3I) and morphologically apoptotic HC nuclei (Fig. 3J). We found that the nuclei of SCs adjacent to dying HCs appeared unaltered morphologically and normally localized on P6 and P15 (data not shown), suggesting that HC loss did not immediately cause SC death.
Developmental Gradient of the HC Phenotype.
We analyzed whole mounts of Rb−/− cochleae on P9, a stage when HCs are more mature, especially those in the basal turns. We still observed cell-cycle reentry on P9, with HCs rounding up and displaying nuclear migration (Fig. 4 A and B). Strikingly, it was only in the most apical tips of Rb−/− cochleae that we observed clusters of HCs containing up to four nuclei that were compacted and did not intermix with the cytoplasm and were incompletely compartmentalized (data not shown). Some clusters displayed symmetry (Fig. 4C), reminiscent of symmetric acytokinetic mitoses, consistent with HCs in later stages of mitosis occasionally observed within the apical region (Fig. 3F).
The OHC maturation marker prestin is normally expressed in the whole cell membrane by P7 and is almost completely absent from the apical and basal cell poles in later developmental stages (18, 19). In contrast to the complete lack of prestin expression in Rb−/− HC precursors (10), most OHCs in Rb−/− mice on P9 displayed the mature prestin expression pattern, but this pattern was abnormal in OHCs entering the cell cycle (Fig. 4).
Discussion
Roles of Rb in Various Phases of the Cell Cycle.
In contrast to other studies in which germ-line or tissue-specific deletions of Rb or other cell-cycle regulators led to the gradual loss of HCs (2, 10, 20–22), our study showed that HC responses were rapid and fairly synchronized. Within 4–5 days after induction and 2–3 days after acute loss of Rb gene function, ≈40% of cochlear HCs (Fig. 3) had reentered the cell cycle, and ≈10% had already died (Fig. 2E), demonstrating the overriding role of Rb in maintaining the quiescence of postnatal HCs. With respect to the time course of cell-cycle reentry upon acute loss of Rb, our in vivo findings were strikingly similar to those of an in vitro study performed in mouse embryonic fibroblasts (23). In addition to controlling the G1/S checkpoint, Rb plays various roles during the cell cycle (24–26). This is reflected by the presence of kidney-shaped and bilobed nuclei in some Rb−/− HCs. Although the vast majority of mitotic Rb−/− HCs we observed were in prophase, we also detected HCs in later stages (Fig. 3F). Thus, the absence of supernumerary HCs and the accumulation of HC clusters point to defects in completing cytokinesis. Cycling myocardiocytes have been shown to arrest at different stages, including mitosis and cytokinesis, and only a fraction underwent cell division, whereas, under certain insults, some postmitotic neurons reentered the S phase but died before the M phase (27). It remains open how inactivation of Rb triggers HC death in various phases of the cell cycle, as we observed, and experiments focused on cell-cycle- or apoptosis-associated Rb pathway genes will be necessary. Although other pocket domain proteins (e.g., p130 and p107) can compensate for specific functions of Rb (28–32), the dramatic phenotype observed in our study can be simply explained by the reported absence of other pocket domain proteins in postnatal HCs (2).
Responses to Rb Loss Depend on the Differentiation Stages of HCs.
Responses to Rb loss in postnatal cochlear HCs are different from those in embryonic undifferentiated HC precursors. When Rb was absent before the cell-cycle exit, ongoing proliferation led to supernumerary HCs and SCs, some of which were functional and escaped death on E18.5 (2, 9). Such proliferation did not occur when Rb was inactivated in postnatal HCs, as shown in our study; instead, rapid cell-cycle reentry and subsequent cell death within all cochlear regions ensued. It is likely that the ablation of Rb in previous embryonic studies (9, 10) simply delayed cell-cycle exit, resulting in an increased number of hair cells, similar to the consequences of ablating several other cell-cycle regulators (20–22). It would therefore be interesting in the future to directly test whether the loss of Rb in early postmitotic, embryonic HC, and SC precursors at approximately E14 also causes cell-cycle reentry, leading either to rapid proliferation and generation of additional HCs and SCs (10) or to rapid cell death as reported here. Using a mouse model in which Rb had been deleted in the germ line, Mantela et al. (2) described increased apoptosis of Rb-null proliferating HC precursors at embryonic ages; we thus expect a similar outcome after acute inactivation at approximately E14.
Interestingly, we also observed variations of responses to Rb inactivation between basal and apical turns of the cochlea. HC clusters were observed in only the most apical tips of Rb−/− cochleae. During early postnatal development, apical HCs are less mature, resembling developing embryonic HCs, whereas basal HCs are more mature, resembling adult HCs (33). It appears that the least differentiated cells in our study, located in the apical tips, had undergone endoproliferation (acytokinetic mitosis) to form multinucleated clusters. In a previous study, similar multinucleated HCs were observed in late embryonic stages in germ line-mutated (Rb−/−) mice (2). Despite this similarity, it remains possible that HC clusters observed in our study are fusion products of multiple dividing HCs and that this property is associated with only developmentally younger and less differentiated HCs. Our findings further support a “time window” for the generation of supernumerary HCs, as suggested in ref. 34. Interestingly, a trend toward earlier loss of OHCs is apparent, although not significant. It might reflect subtle differences between the two types of HCs with regard to their developmental stages and kinetics in response to the acute loss of Rb function. Alternatively, it might simply reflect slight differences between IHCs and OHCs regarding Cre activity (ref. 14 and Fig. 1D).
Roles of Rb in Postnatal HC Maturation.
The presence of prestin in Rb-null OHCs in our model strongly suggests that Rb is not required during postnatal OHC maturation for the continued expression of prestin. However, prestin was completely absent in OHCs after Rb inactivation in early embryonic HC precursors (10). Again, these findings highlight the importance of developmental stages of HCs in their responses to Rb inactivation and suggest that Rb indirectly induces OHC-specific gene expression before the loss of Rb function induced in our study (i.e., before P2).
Implications for HC Regeneration Studies in Mice and Humans.
Regenerating HCs by inactivating Rb or other cell-cycle regulators in residual postnatal HCs is a daunting task. Even if transient Rb inactivation in the remaining HCs were achieved, the cell surveillance machinery would have to be manipulated simultaneously to keep cells alive without immortalizing them. It remains unknown whether the HCs in our study died from the loss of Rb gene function or from an age-dependent decline in proliferative ability. Our HC-specific, inducible Cre mouse model will be helpful to address this critical question by manipulating other cell-cycle regulators.
Inherited predisposition to the childhood malignancy retinoblastoma occurs in individuals carrying a germ-line mutation of one allele of Rb and loss of the second Rb allele through somatic mutation in retinoblastoma tumors (35). Hearing loss in children treated for this eye disease is associated with chemotherapy (36). Indeed, our model suggests that the loss of the second Rb allele in individual HCs would result in immediate cell-autonomous cell death, without affecting hearing function or causing dysplasia. A possible link between Rb and hearing disorders in humans is an autosomal-dominant auditory neuropathy, which has been mapped to chromosome 13 (37). The marker with the highest LOD score is localized in intron 2 of the Rb gene, suggesting that Rb is a candidate deafness gene in humans.
Materials and Methods
Mouse Models.
Rblox/lox mice (13) were kindly provided by A. Berns (The Netherlands Cancer Institute, Amsterdam, The Netherlands) through the National Cancer Institute Mouse Models of Human Cancers Consortium. The care and use of the mice during the course of this study were approved by the Institutional Animal Care and Use Committee at St. Jude Children's Research Hospital.
Tissue Preparation and DNA Isolation.
Cochleae were dissected and processed as described in ref. 16. PCR primers and procedures used for genotyping and the application of tamoxifen were as described in refs. 38 (Rb) and 14 (Cre and lacZ).
Immunostaining, lacZ Staining and Microscopic Analysis.
Antibodies against prestin (1:200; Santa Cruz), myosin7a (1:200; Proteus BioSciences), or phosphorylated Ser-10 of histone H3 (1:100; Abcam) and secondary antibodies (1:1,000; Alexa Fluor 594 or 488) were used. A fluorescence (Olympus) or a multiphoton (Zeiss LSM, Axioplan) microscope was used in confocal mode for imaging analysis. For high-resolution fluorescence microscopy, cryosections were treated with Carnoy's fixative (3 vol of absolute methanol and 1 vol of glacial acetic acid), washed in PBS, and stained with DAPI. Images were captured with a Nikon Labophot 2 microscope, using Metamorph software, Version 6.2r6, and were deconvoluted by using AutoDeblur software, Version X1.4.1 (Media Cybernetics). LacZ staining of cochleae was performed as described in ref. 14.
Hair Cell Counts.
The numbers of IHCs and OHCs per 100 μm of whole mount length within specific turns were calculated and compared with those of littermates for each age group as a percentage (Rb−/−/Rb+/−). To prevent movements of the specimens during microscopic analysis, whole mounts were prepared by using a hardening medium (Vectashield HardSet with DAPI; Vector Laboratories). We chose a representative region within a specific cochlear turn and determined its length from within the inner row of OHCs, using LSM image browser software (Zeiss). The presence or absence of HCs was determined on the basis of two independent HC markers (prestin and myosin7a), using confocal microscopy. The length of the analyzed regions was 614.9 ± 61.0 μm (n = 61) containing 233.7 ± 26.0 OHCs (n = 20) and 71.4 ± 7.4 IHCs (n = 22) in Rb+/− mice.
Proliferation and TUNEL Staining.
Undiluted BrdU labeling reagent (15 μl per gram of body weight; Roche) was used. Cryosections were stained with the myosin7a antibody and then treated with 2 N of HCl for 10 min at room temperature, washed three times in PBS and then in 0.1 M Tris (pH 8.0), washed again twice in PBS, and stained for BrdU (Roche). TUNEL staining was performed on cryosections, using reagents from the ApopTag red in situ apoptosis detection kit (Chemicon).
ACKNOWLEDGMENTS.
We thank Drs. M. Dyer, B. Schwers, and K. Kitagawa for advice and for sharing reagents; Y. Tian for discussion; X. Wu for technical advice; and M. Roussel for critical comments. This work was supported in part by National Institutes of Health Grants DC06471, DC05168, DC008800, CA21765, CA023944, A096832, and NS044172; the Deafness Research Foundation; the Jean-François St.-Denis Fellowship in Cancer Research from the Canadian Institutes of Health Research; the American Lebanese Syrian Associated Charities of St. Jude Children's Research Hospital; and a Hartwell Individual Biomedical Research Award (J.Z.).
Footnotes
The authors declare no conflict of interest.
This article is a PNAS Direct Submission.
References
- 1.Lee YS, Liu F, Segil N. Development (Cambridge, UK) 2006;133:2817–2826. doi: 10.1242/dev.02453. [DOI] [PubMed] [Google Scholar]
- 2.Mantela J, Jiang Z, Ylikoski J, Fritzsch B, Zacksenhaus E, Pirvola U. Development (Cambridge, UK) 2005;132:2377–2388. doi: 10.1242/dev.01834. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Ruben RJ. Acta Otolaryngol. 1967;220(Suppl):1–44. [PubMed] [Google Scholar]
- 4.Kelley MW. Brain Res. 2006;1091:172–185. doi: 10.1016/j.brainres.2006.02.062. [DOI] [PubMed] [Google Scholar]
- 5.Corwin JT, Oberholtzer JC. Neuron. 1997;19:951–954. doi: 10.1016/s0896-6273(00)80386-4. [DOI] [PubMed] [Google Scholar]
- 6.Ryals BM, Rubel EW. Science. 1988;240:1774–1776. doi: 10.1126/science.3381101. [DOI] [PubMed] [Google Scholar]
- 7.Taylor RR, Forge A. J Comp Neurol. 2005;484:105–120. doi: 10.1002/cne.20450. [DOI] [PubMed] [Google Scholar]
- 8.Sherr CJ. Cancer Res. 2000;60:3689–3695. [PubMed] [Google Scholar]
- 9.Sage C, Huang M, Karimi K, Gutierrez G, Vollrath MA, Zhang DS, Garcia-Anoveros J, Hinds PW, Corwin JT, et al. Science. 2005;307:1114–1118. doi: 10.1126/science.1106642. [DOI] [PubMed] [Google Scholar]
- 10.Sage C, Huang M, Vollrath MA, Brown MC, Hinds PW, Corey DP, Vetter DE, Chen ZY. Proc Natl Acad Sci USA. 2006;103:7345–7350. doi: 10.1073/pnas.0510631103. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Wikenheiser-Brokamp KA. Cell Mol Life Sci. 2006;63:767–780. doi: 10.1007/s00018-005-5487-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Nagy A. Genesis. 2000;26:99–109. [PubMed] [Google Scholar]
- 13.Marino S, Vooijs M, van Der Gulden H, Jonkers J, Berns A. Genes Dev. 2000;14:994–1004. [PMC free article] [PubMed] [Google Scholar]
- 14.Chow LM, Tian Y, Weber T, Corbett M, Zuo J, Baker SJ. Dev Dyn. 2006;235:2991–2998. doi: 10.1002/dvdy.20948. [DOI] [PubMed] [Google Scholar]
- 15.Soriano P. Nat Genet. 1999;21:70–71. doi: 10.1038/5007. [DOI] [PubMed] [Google Scholar]
- 16.Wu X, Gao J, Guo Y, Zuo J. Brain Res Mol Brain Res. 2004;126:30–37. doi: 10.1016/j.molbrainres.2004.03.020. [DOI] [PubMed] [Google Scholar]
- 17.Pearson RA, Luneborg NL, Becker DL, Mobbs P. J Neurosci. 2005;25:10803–10814. doi: 10.1523/JNEUROSCI.2312-05.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Weber T, Zimmermann U, Winter H, Mack A, Kopschall I, Rohbock K, Zenner HP, Knipper M. Proc Natl Acad Sci USA. 2002;99:2901–2906. doi: 10.1073/pnas.052609899. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Winter H, Braig C, Zimmermann U, Geisler HS, Franzer JT, Weber T, Ley M, Engel J, Knirsch M, Bauer K, et al. J Cell Sci. 2006;119:2975–2984. doi: 10.1242/jcs.03013. [DOI] [PubMed] [Google Scholar]
- 20.Chen P, Segil N. Development (Cambridge, UK) 1999;126:1581–1590. doi: 10.1242/dev.126.8.1581. [DOI] [PubMed] [Google Scholar]
- 21.Chen P, Zindy F, Abdala C, Liu F, Li X, Roussel MF, Segil N. Nat Cell Biol. 2003;5:422–426. doi: 10.1038/ncb976. [DOI] [PubMed] [Google Scholar]
- 22.Lowenheim H, Furness DN, Kil J, Zinn C, Gultig K, Fero ML, Frost D, Gummer AW, Roberts JM, Rubel EW, et al. Proc Natl Acad Sci USA. 1999;96:4084–4088. doi: 10.1073/pnas.96.7.4084. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Sage J, Miller AL, Perez-Mancera PA, Wysocki JM, Jacks T. Nature. 2003;424:223–228. doi: 10.1038/nature01764. [DOI] [PubMed] [Google Scholar]
- 24.Hernando E, Nahle Z, Juan G, Diaz-Rodriguez E, Alaminos M, Hemann M, Michel L, Mittal V, Gerald W, Benezra R, et al. Nature. 2004;430:797–802. doi: 10.1038/nature02820. [DOI] [PubMed] [Google Scholar]
- 25.van Deursen JM. Cancer Cell. 2007;11:1–3. doi: 10.1016/j.ccr.2006.12.006. [DOI] [PubMed] [Google Scholar]
- 26.Zacksenhaus E, Jiang Z, Chung D, Marth JD, Phillips RA, Gallie BL. Genes Dev. 1996;10:3051–3064. doi: 10.1101/gad.10.23.3051. [DOI] [PubMed] [Google Scholar]
- 27.Bettencourt-Dias M, Mittnacht S, Brockes JP. J Cell Sci. 2003;116:4001–4009. doi: 10.1242/jcs.00698. [DOI] [PubMed] [Google Scholar]
- 28.Chen D, Livne-bar I, Vanderluit JL, Slack RS, Agochiya M, Bremner R. Cancer Cell. 2004;5:539–551. doi: 10.1016/j.ccr.2004.05.025. [DOI] [PubMed] [Google Scholar]
- 29.Donovan SL, Schweers B, Martins R, Johnson D, Dyer MA. BMC Biol. 2006;4:14. doi: 10.1186/1741-7007-4-14. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.MacPherson D, Sage J, Kim T, Ho D, McLaughlin ME, Jacks T. Genes Dev. 2004;18:1681–1694. doi: 10.1101/gad.1203304. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Robanus-Maandag E, Dekker M, van der Valk M, Carrozza ML, Jeanny JC, Dannenberg JH, Berns A, te Riele H. Genes Dev. 1998;12:1599–1609. doi: 10.1101/gad.12.11.1599. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Zhang J, Gray J, Wu L, Leone G, Rowan S, Cepko CL, Zhu X, Craft CM, Dyer MA. Nat Genet. 2004;36:351–360. doi: 10.1038/ng1318. [DOI] [PubMed] [Google Scholar]
- 33.Rubel EW, Born DE, Deitch JS, Durham D. In: Hearing Science: Recent Advances. Berlin CI, editor. San Diego: College-Hill Press; 1984. pp. 109–157. [Google Scholar]
- 34.Kelley MW, Xu XM, Wagner MA, Warchol ME, Corwin JT. Development (Cambridge, UK) 1993;119:1041–1053. doi: 10.1242/dev.119.4.1041. [DOI] [PubMed] [Google Scholar]
- 35.Laurie NA, Donovan SL, Shih CS, Zhang J, Mills N, Fuller C, Teunisse A, Lam S, Ramos Y, Mohan A, et al. Nature. 2006;444:61–66. doi: 10.1038/nature05194. [DOI] [PubMed] [Google Scholar]
- 36.Lambert MP, Shields C, Meadows AT. Pediatr Blood Cancer. 2008;50(2):223–226. doi: 10.1002/pbc.21155. [DOI] [PubMed] [Google Scholar]
- 37.Kim TB, Isaacson B, Sivakumaran TA, Starr A, Keats BJ, Lesperance MM. J Med Genet. 2004;41:872–876. doi: 10.1136/jmg.2004.020628. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Vooijs M, van der Valk M, te Riele H, Berns A. Oncogene. 1998;17:1–12. doi: 10.1038/sj.onc.1202169. [DOI] [PubMed] [Google Scholar]